Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies.

British Journal of Pharmacology
Zinnia P Parra-GuillenIñaki F Troconiz

Abstract

Acute intermittent porphyria (AIP) results from haplo-insufficiency of the porphobilinogen deaminase (PBGD) gene encoding the third enzyme in the haem biosynthesis pathway. As liver is the main organ of pathology for AIP, emerging therapies that restore enzyme hepatic levels are appealing. The objective of this work was to develop a mechanistic-based computational framework to describe the effects of novel PBGD mRNA therapy on the accumulation of neurotoxic haem precursors in small and large animal models. Liver PBGD activity data and/or 24-hr urinary haem precursors were obtained from genetic AIP mice and wild-type mice, rats, rabbits, and macaques. To mimic acute attacks, porphyrogenic drugs were administered over one or multiple challenges, and animals were used as controls or treated with different PBGD mRNA products. Available experimental data were sequentially used to build and validate a semi-mechanistic mathematical model using non-linear mixed-effects approach. The developed framework accounts for the different biological processes involved (i.e., mRNA sequence, release from lipid nanoparticle and degradation, mRNA translation, increased PBGD activity in liver, and haem precursor metabolism) in a simplified mechanisti...Continue Reading

References

Nov 16, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·C M VargaD A Lauffenburger
Mar 16, 2005·Annals of Internal Medicine·Karl E AndersonRobert J Desnick
Jun 21, 2005·International Journal of Pharmaceutics·Yuma YamadaHideyoshi Harashima
Jan 12, 2008·Annual Review of Medicine·Janet Woodcock, Raymond Woosley
Aug 19, 2008·International Journal of Pharmaceutics·Rumiko MoriguchiHideyoshi Harashima
Nov 18, 2008·Molecular Genetics and Metabolism·Robert C GriggsUNKNOWN Rare Diseases Clinical Research Network
Jun 6, 2009·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Pedro BerraondoIñaki F Trocóniz
Jan 20, 2010·Mutation Research·Carmel Mothersill, Colin Seymour
Mar 17, 2010·Lancet·Hervé PuyJean-Charles Deybach
Apr 14, 2010·Pharmaceutical Research·Zinnia P Parra-GuillénIñaki F Trocóniz
Jul 24, 2010·British Journal of Pharmacology·Carol KilkennyUNKNOWN NC3Rs Reporting Guidelines Working Group
Feb 9, 2011·The AAPS Journal·Martin BergstrandMats O Karlsson
Jun 4, 2011·PloS One·Baltazar D AgudaElliott D Crouser
Jun 28, 2011·Nature Reviews. Drug Discovery·Marc Dunoyer
Jul 14, 2012·Blood·Manisha Balwani, Robert J Desnick
Nov 2, 2012·Journal of Inherited Metabolic Disease·George ElderJean-Charles Deybach
Apr 17, 2013·Clinical Pharmacology and Therapeutics·P A MilliganR L Lalonde
Jan 1, 2012·CPT: Pharmacometrics & Systems Pharmacology·D R Mould, R N Upton
Jan 11, 2014·Nature Biotechnology·Michael HayJesse Rosenthal
Aug 5, 2014·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Kenneth Es PooleCesar Libanati
Jul 6, 2015·Clinics and Research in Hepatology and Gastroenterology·Zoubida KarimHervé Puy
May 24, 2016·Journal of Hepatology·Delia D'AvolaGloria González-Aseguinolaza
Nov 3, 2016·Expert Reviews in Molecular Medicine·Antonio FontanellasPedro Berraondo
Dec 17, 2016·British Journal of Haematology·Penelope E SteinDavid C Rees
Aug 1, 2012·Clinical Pharmacokinetics·Tony K L KiangMary H H Ensom
Nov 7, 2017·Clinical Pharmacology and Therapeutics·John P GibbsSreeneeranj Kasichayanula
Apr 15, 2018·Molecular Therapy : the Journal of the American Society of Gene Therapy·Staci SabnisKerry E Benenato
Oct 10, 2018·Nature Medicine·Lei JiangAntonio Fontanellas
Jan 15, 2019·Molecular Genetics and Metabolism·Diego Vera-YuncaZinnia P Parra-Guillén
Jan 18, 2019·Clinical Pharmacology and Therapeutics·Yaning WangIssam Zineh
Feb 7, 2019·The New England Journal of Medicine·Eliane SardhKarl E Anderson
May 19, 2019·Journal of Hepatology·Antonio FontanellasJean-Charles Deybach
Nov 12, 2019·British Journal of Pharmacology·Stephen P H AlexanderUNKNOWN CGTP Collaborators

❮ Previous
Next ❯

Citations

Feb 4, 2021·British Journal of Pharmacology

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.